# LMBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lmbio

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.lanmabio.com
- Latest round: Series A (Dec 13, 2024)
- Investors on record: 3

## About

Founded in 2020 and based in Suzhou, China, LMBio is a biotech company that focuses on the research and development of cellular immunotherapy products with TILs therapy as the core. Dr. Feng li, the company's CSO, worked in the TIL laboratory at the MD Anderson Cancer Research Center in the United States. In December 2024, LMBio closed a series A funding from new investors Tianjin Venture Capital, Huagai Capital, Tasly Capital and other undisclosed investors.

The company's main product is TILS LM103 injection which release cytotoxin to directly kill tumor cells.

The company generates revenue by providing cellular immunotherapy products focusing on tumor infiltrating lymphocytes (TILs) therapy.

## Funding rounds

- Series A, Dec 13, 2024 — Tianjin Venture Capital, Huagai Capital, Tasly Capital
- Angel, Apr 21, 2021 — Huagai Capital

## Investors

- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Angel, Series A
- Tianjin Venture Capital (https://capitalatlas.ai/funds/tianjin-venture-capital) — Series A
- Tasly Capital — Series A